Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Datametrex AI Ltd V.DM

Alternate Symbol(s):  DTMXF

Datametrex AI Limited is a technology-focused company with exposure to artificial intelligence, healthcare, and mobile gaming. It is focused on collecting, analyzing and presenting structured and unstructured data using machine learning and artificial intelligence. The Company's products include AnalyticsGPT, Cyber Security, and Healthcare. AnalyticsGPT platform scans vast data streams from social media, news, blogs, forums, messengers, enterprise data, and the dark Web, creating predictive analytics. Cyber Security is a deep analytics platform that captures, structures, and visualizes vast amounts of unstructured social media data, which is used as a discovery tool that allows organizations to make decisions. It offers Nexa Products, which consists of NexaSecurity and NexaSMART. Healthcare consists of Imagine Health Centres, a multidisciplinary healthcare facility, and Medi-Call, a telehealth platform. The Company also offers a mobile blockchain game, Cereal Crunch.


TSXV:DM - Post by User

Post by Resilience19on Feb 15, 2021 10:42am
416 Views
Post# 32567893

25,000 tests/week in Q2

25,000 tests/week in Q2
This is only speculation at this time but given the tests/week having tripled from Q4 to Q1 (4,000/wk to 12,000/wk), I wouldn't be surprises, given the current context (variants threat, availability of non-intrusive spit test etc), to see test double again in Q2, to 25,000 or so. Furthermore, as DM appears to be building capacity, as demand increases, I wouldn't be surprised to see this figure, yet again, double to 50,000ish/wk during Q3. Afterwards, as nationwide immunization-driven herd immunity builds up, it may be that these figures will decrease, but that is highly dependent on whether additional new variants don't wreck havoc. In short, we may end up being in a linger term testing pattern, although margins would likely decrease as competition and tests availabilities increase. Regardless 2021 is bound to be a very interesting COVID-related income generating year at that current 12,000/wk tests is nimble compared to what's to come. My two cents.
<< Previous
Bullboard Posts
Next >>